NSE LAURUSLABS · BSE 540222 · Biotechnology & Drugs · NIFTY 500

Laurus Labs Share Price

Market closed · NSE price as of Thu 24 Sep, 8:53 AM IST
₹2,037.50 ▲ +₹0.81 · 0.04%
Day range · 24 Sep
₹2,020.10Low₹2,054.55High
52-week range
₹822.85Low · 26 Sep 2025₹2,037.45High · 23 Sep 2026

Laurus Labs Overview

Where the price stands, how it has moved and how it sits against its averages.

Laurus Labs shares last traded at ₹2,037.50 on the NSE, up 0.04% on the day. That is 0.0% below the 52-week high of ₹2,037.45 and 147.6% above the 52-week low of ₹822.85. The stock trades at 100.60× earnings, above the sector average of 36.50. Its market value is ₹1,09,991 Cr.

Price returns

1 Day▲ +0.04%
1 Week0.00%
This month▲ +6.21%
3 Months▲ +39.87%
6 Months▲ +98.73%
This year▲ +83.57%
1 Year▲ +123.50%

Against the market: 1 Month ▲ +11.60% · 3 Months ▲ +43.91% · 6 Months ▲ +99.91% · This year ▲ +109.07% · 1 Year ▲ +145.23%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Mon 26 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 6 of 6

  1. Today's price₹2,037.50
  2. 5-day average₹1,966.32 ▲ price 3.6% above
  3. 10-day average₹1,955.64 ▲ price 4.2% above
  4. 20-day average₹1,916.38 ▲ price 6.3% above
  5. 50-day average₹1,805.27 ▲ price 12.9% above
  6. 100-day average₹1,589.49 ▲ price 28.2% above
  7. 300-day average₹1,311.39 ▲ price 55.4% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Laurus Labs Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
6,813
Net profit₹ crore · losses below zero
984
889

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹6,813 Cr ▲ +22.7% ₹889 Cr 13.0% ₹16.45 ₹2.00
FY 2025 ₹5,554 Cr ▲ +10.2% ₹358 Cr 6.5% ₹6.64 ₹1.20
FY 2024 ₹5,041 Cr ▼ −16.6% ₹161 Cr 3.2% ₹2.97 ₹0.80
FY 2023 ₹6,041 Cr ▲ +22.4% ₹790 Cr 13.1% ₹14.64 ₹1.20
FY 2022 ₹4,936 Cr ▲ +2.5% ₹828 Cr 16.8% ₹15.35 —
FY 2021 ₹4,814 Cr ▲ +70.0% ₹984 Cr 20.4% ₹18.28 —
FY 2020 ₹2,832 Cr — ₹255 Cr 9.0% ₹4.79 —

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
50%
50%
  • Total assets₹10,511 Cr
  • Total liabilities₹5,211 Cr
  • Shareholders' equity₹5,300 Cr
  • Total debt₹2,518 Cr
  • Cash & investments₹113 Cr
  • Current ratio1.33×
  • Revenue growth, 5 yr7.19% a year
  • EPS growth, 5 yr−2.09% a year
  • Operating margin (TTM)21.28%
  • Net margin (TTM)15.00%

Cash flow — FY26

Operating activities
▲ ₹1,624 Cr
Investing activities
▼ −₹1,089 Cr
Financing activities
▼ −₹525 Cr
Free cash flow
▲ ₹554 Cr
Net change in cash
▲ ₹13 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue2,831.724,813.514,935.576,040.555,040.835,553.966,812.90
Cost of revenue1,580.802,355.122,452.793,164.812,837.242,862.813,134.78
Gross profit1,250.922,458.392,482.782,875.742,203.592,691.153,678.12
Operating expenses2,448.803,467.053,761.654,746.914,645.984,928.775,507.28
Operating income382.921,346.461,173.921,293.64394.85625.191,305.62
Depreciation187.32205.07251.49324.08384.58430.09480.05
Profit before tax293.611,301.111,083.851,108.94236.36484.291,181.88
Tax38.34317.29251.42312.3068.15129.88292.03
Net profit255.27983.58827.52790.11160.55358.32888.79
EPS (₹)4.7918.2815.3514.642.976.6416.45
Dividend per share (₹)———1.200.801.202.00

Laurus Labs vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Laurus Labs This stock ₹2,037.50 ▲ +0.04% ₹1,09,991 Cr 100.60 20.76 15.19% 15.00% 0.10%
Sun Pharmaceutical Industries ₹1,852.00 ▼ −0.70% ₹4,44,346 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,623.50 ▲ +0.28% ₹2,55,474 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,935.65 ▼ −0.89% ₹1,87,730 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,398.30 ▲ +1.33% ₹1,12,963 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,180.00 ▲ +0.90% ₹1,17,705 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Laurus Labs shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
27.5%
28.0%
10.2%
34.4%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter27.59%27.49%27.49%27.47% ▼ −0.02 pts
FII26.17%26.52%25.82%28.00% ▲ +2.18 pts
MF8.53%9.49%11.22%10.15% ▼ −1.07 pts
Other37.71%36.50%35.47%34.38% ▼ −1.09 pts

Laurus Labs Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Laurus LabsBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
100.60
▲ 176% above the sector average of 36.50
P/E, 12-month rangeLow 20.00 · high 190.56
47%
Today's P/E sits 47% of the way from its low to its high
P/BPrice ÷ book value per share
20.76
P/SMarket cap ÷ last 12 months' revenue
15.13
P/CFPrice ÷ cash flow per share
69.65
PEGP/E ÷ earnings growth rate
25.49

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
61.29%
▲ above its 5-yr average of 49.08%
Operating marginKept after running costs
21.28%
▲ above its 5-yr average of 16.89%
Pre-tax marginKept before tax
19.79%
▲ above its 5-yr average of 14.43%
Net marginKept as profit
15.00%
▲ above its 5-yr average of 10.72%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
18.19%
▲ above its 5-yr average of 15.19%
Return on assetsProfit on everything it owns
8.97%
▲ above its 5-yr average of 7.51%
Return on investmentProfit on long-term capital
14.34%
▲ above its 5-yr average of 11.95%
Return on capital employedProfit before interest and tax on equity + debt
17.40%

Growth Is the business getting bigger?

Revenue — last 12 months
+22.6%
▲ growing
Revenue — 3 yr, a year
+4.1%
▲ growing
Revenue — 5 yr, a year
+7.2%
▲ growing
Net profit — 3 yr, a year
+4.0%
▲ growing
Net profit — 5 yr, a year
−2.0%
▼ shrinking
EPS — last 12 months
+114.5%
▲ growing (off the scale)
EPS — 3 yr, a year
+4.0%
▲ growing
EPS — 5 yr, a year
−2.1%
▼ shrinking
Dividend — 3 yr, a year
+18.6%
▲ growing
Book value — 5 yr, a year
+15.2%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.48×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
1.33×
• Adequate
Quick ratioLike the current ratio, without inventory
0.68×
! Tight
Interest coverOperating profit ÷ interest to pay
10.23×
✓ Strong
Payout ratioShare of profit paid as dividend
12.16%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹20.23
Book value
₹98.17
Cash flow
₹29.19
Dividend
₹2.00
Revenue
₹134.48

The share price is 20.76× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 109 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year123.68
Current Dividend Yield - Common Stock Primary Issue, LTM0.10
Price to Book - most recent fiscal year20.72
P/E Basic excluding extraordinary items - TTM74.91
P/E including extraordinary items - TTM100.57
P/E excluding extraordinary items low, trailing 12 months20.00
Price to Tangible Book - most fiscal year21.83
Price to sales - most recent fiscal year16.13
Dividend Yield - indicated annual dividend divided by closing price0.10
Price to Cash Flow per share - trailing 12 month69.65
Peg Ratio25.49
Price to Free Cash Flow per Share - most recent fiscal year235.22
P/E Normalized, most recent fiscal year122.96
P/E excluding extraordinary items high, trailing 12 months190.56
P/E excluding extraordinary items, most recent fiscal year quarter100.57
Price to sales - trailing 12 month15.12
Net Debt, LFY24,058.20

Per share

Cash Flow per share - trailing 12 month29.19
Cash Flow per share - most recent fiscal year25.35
EPS including extraordinary items - trailing 12 month20.23
EPS including extraordinary items - most recent fiscal year16.45
EBITD per share - trailing 12 month37.62
Revenue/share - trailing 12 month134.48
EPS excluding extraordinary items - trailing 12 month20.23
EPS Basic excluding extraordinary items - most recent fiscal year16.47
EPS Basic excluding extraordinary items - trailing 12 month20.26
Book value per share - most recent fiscal year98.18
Dividend per share - most recent fiscal year2.00
Revenue/share - most recent fiscal year126.06
EPS Normalized - most recent fiscal year16.54
Book value (tangible) per share - most recent fiscal year93.27
Dividends per share - trailing 12 month2.00
EPS excluding extraordinary items - most recent fiscal year16.45
Cash per share - most recent fiscal year2.09

Margins

Operating margin - trailing 12 month21.28
Gross Margin - 5 year average49.08
Operating margin - 1st historical fiscal year19.16
Operating Margin - 5 year average16.89
Net Profit Margin % - 1st historical fiscal year13.06
Gross Margin - 1st historical fiscal year53.99
Net Profit Margin % - trailing 12 month15.00
Net Profit Margin - 5 year average10.72
Pretax Margin - 5 year average14.43
Pretax margin - 1st historical fiscal year17.35
Pretax margin - trailing 12 month19.79
Free Operating Cash Flow/Revenue, 5 Year Average0.46
Gross Margin - trailing 12 month61.29

Growth

EPS Change %, TTM over TTM114.46
Revenue growth rate, 5 year7.19
EPS growth rate, 5 year−2.09
Revenue Change % - most recent quarter 1 year ago29.10
Growth rate% - dividend, 3 year18.56
Growth rate% - EPS, 3 year3.95
Revenue/share (5 yr growth)7.10
Tangible Book Value, Total Equity, 5 Year CAGR16.54
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR4.05
Capital Spending growth rate, 5 year9.21
Revenue Change %, TTM over TTM22.62
Growth rate% - Revenue, 3 year4.09
Book value per share growth rate, 5 year15.19
EPS Change % - most recent quarter 1 year ago125.17
Net Profit Margin growth rate, 5 year−8.57
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR2.85
Total Debt, 5 Year CAGR11.19

Financial strength

Net Interest coverage - most recent fiscal year10.23
Free Cash Flow - most recent fiscal year4,672.20
LT debt/equity - most recent fiscal year0.14
Quick ratio - most recent fiscal year0.68
Payout ratio - trailing 12 month9.87
Current ratio - most recent fiscal year1.33
Current EV/Free Cash Flow, LFY526.34
Total debt/total equity - most recent fiscal year0.48
Net Interest coverage - trailing 12 month9.99
Payout ratio - most recent fiscal year12.15

Returns & efficiency

Return on average equity - 5 year average15.19
Net Income/employee - trailing 12 month15,45,205.00
Revenue/employee - most recent fiscal year1,03,02,280.00
Return on investment - most recent fiscal year14.34
Return on average assets - most recent fiscal year8.97
Receivables turnover - most recent fiscal year3.27
Inventory turnover - most recent fiscal year1.47
Revenue/employee - trailing 12 month1,02,98,400.00
Return on average assets - 5 year average7.51
Net Income/employee - most recent fiscal year13,45,607.00
Asset turnover - most recent fiscal year0.69
Return on average equity - most recent fiscal year18.19
Return on investment - 5 year average11.95

Price & volume

Market Cap1,10,742.40
52 week Low Date26 Sep 2025
Price - 1 Day % Change1.37
Relative (S&P500) price percent change - 13 week43.91
Avg trading volume last 10 days1.89
Price - 13 week price percent change39.87
Price - 52 week price percent change123.50
Avg Trading Volume Last 3 months57.06
Price - 5 Day % Change6.74
Price % Change Month To Date6.21
Relative (S&P500) price percent change - 04 week11.60
52 week High Date23 Sep 2026
Price - 26 week price percent change98.73
PDATE23 Sep 2026
Price - YTD price percent change83.57
Relative (S&P500) price percent change - 52 week145.23
NPRICE2,034.00
Relative (S&P500) price percent change - 26 week99.91
52 week Low823.10
52 week High2,037.20
Beta0.96
Relative (S&P500) price percent change - Year to Date109.07

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹2.00
  • Dividend yield0.10%
  • Payout ratio12.16%
  • Latest dividend₹1.20 per share · 8 May 2026

Corporate calendar

  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹1.20 per share · 60% · Interim dividend
  • BoardAudited Results & Interim Dividend
  • BoardQuarterly Results
  • Dividend₹0.80 per share · 40% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • BoardQuarterly Results
Show 14 older events
  • MeetingAnnual General Meeting
  • Dividend₹0.80 per share · 40% · Interim dividend
  • BoardAudited Results & Interim Dividend
  • BoardQuarterly Results
  • Dividend₹0.40 per share · 20% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • MeetingPostal Ballot
  • MeetingAnnual General Meeting
  • Dividend₹0.40 per share · 20% · Interim dividend
  • Dividend₹0.40 per share · 20% · Interim dividend
  • MeetingAnnual General Meeting
  • Dividend₹1.20 per share · 60% · Interim dividend
  • MeetingPostal Ballot
  • Dividend₹0.80 per share · 40% · Interim dividend

About Laurus Labs

Biotechnology & Drugs

Laurus Labs Limited is an India-based company. The Company is a pharmaceutical manufacturing organization. It is engaged in developing and manufacturing active pharmaceutical ingredients (APIs) and intermediates. It supplies anti-retroviral APIs and intermediates. It provides contract and custom manufacturing solutions, allowing client organizations to outsource various stages of the manufacturing process. It is also engaged in development and manufacturing of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements catering to the needs of stem cells and regenerative medicine, vaccines and biological drugs, cultured meat, and cell-culture media manufacturing. It offers precision fermentation as a contract development and manufacturing organization (CDMO) service. Its service is offered to protein companies and bio-manufacturers operating across healthcare, food, nutrition, personal care, and bio-based materials markets.

Key people

  • Satyanarayana ChavaChief Executive Officer, Executive Director
  • Venkata Vantaram Ravi KumarChief Financial Officer, Executive Director
  • V. Uma Maheswer RaoPresident - Chemical R&D
  • Srinivasa Rao SuryadevaraPresident - Manufacturing and Operations
  • Thomas VersoskyPresident - FDF, North America
  • Sita RamaiahExecutive Vice President - Finance

Company facts

  • NSE symbolLAURUSLABS
  • BSE code540222
  • ISININE947Q01028
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹1,09,991 Cr
  • Revenue (FY26)₹6,813 Cr
  • Net profit (FY26)₹889 Cr

In the News

Recent headlines about Laurus Labs — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Laurus Labs (NSE: LAURUSLABS) last traded at ₹2,037.50 on the NSE, up 0.04% (₹0.81) on the day, as of 24 Sep 2026, 8:53 AM IST. On the BSE it was ₹2,035.70. The day's range was ₹2,020.10 – ₹2,054.55.

Laurus Labs's 52-week high is ₹2,037.45 (23 Sep 2026) and its 52-week low is ₹822.85 (26 Sep 2025). At ₹2,037.50 the share is 0.0% below its high and 147.6% above its low.

Laurus Labs's market capitalisation is ₹1,09,991 Cr (₹1.10L Cr). It is part of the NIFTY 500 index.

Laurus Labs's P/E ratio (trailing 12 months) is 100.60. The sector average is 36.50, so investors pay 176% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹20.23.

Laurus Labs shares are up 123.50% over the last year, up 83.57% so far this year, up 98.73% over 6 months, up 39.87% over 3 months. Over the last year the stock did 145.23% better than the market.

In FY26 (year to Mar 2026), Laurus Labs reported revenue of ₹6,813 Cr (up 22.67% on the year before) and a net profit of ₹889 Cr. Earnings per share were ₹16.45.

Yes. Laurus Labs's latest dividend is ₹1.20 per share (60%, interim dividend), with an ex-date of 8 May 2026. The dividend yield is 0.10%. It has paid 8 dividends in the records shown on this page.

As of Jun 2026: Promoter 27.47%, FII 28.00%, MF 10.15%, Other 34.38%. Promoter holding fell by 0.02 percentage points from Mar 2026.

Laurus Labs's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

No. Laurus Labs has debt — its debt-to-equity ratio is 0.48 and total debt was ₹2,518 Cr in FY26. Its operating profit covers interest 10.23 times.